Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ad-hoc News: ABO Energy GmbH & Co. KGaA (EQS) +++ ABO ENERGY Aktie -12,30%

CARDIOL Aktie

 >CARDIOL Aktienkurs 
0.931 EUR    (TradegateBSX)
Ask: 0.949 EUR / 1071 Stück
Bid: 0.913 EUR / 1115 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
CARDIOL Aktie über LYNX handeln
>CARDIOL Performance
1 Woche: -2,5%
1 Monat: -17,3%
3 Monate: -26,7%
6 Monate: -19,0%
1 Jahr: +4,8%
laufendes Jahr: +9,6%
>CARDIOL Aktie
Name:  CARDIOL THERAPEUTICS CL.A
Land:  Kanada
Sektor:  Gesundheit
ISIN/ Wkn:  CA14161Y2006 / A2PA9E
Symbol/ Ticker:  CT9 (Frankfurt) / CRDL (NASDAQ)
Kürzel:  FRA:CT9, ETR:CT9, CT9:GR, NASDAQ:CRDL
Index:  -
Profil:  Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The comp..
>Volltext..
Marktkapitalisierung:  111.53 Mio. EUR
Unternehmenswert:  95.4 Mio. EUR
Umsatz:  -
EBITDA:  -22.6 Mio. EUR
Nettogewinn:  -21.53 Mio. EUR
Gewinn je Aktie:  -0.22 EUR
Schulden:  0.07 Mio. EUR
Liquide Mittel:  16.48 Mio. EUR
Operativer Cashflow:  -15.2 Mio. EUR
Bargeldquote:  4.96
Umsatzwachstum:  -
Gewinnwachstum:  10.28%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  CARDIOL
Letzte Datenerhebung:  11.11.26
>CARDIOL Kennzahlen
Aktien/ Unternehmen:
Aktien: 120.66 Mio. St.
Frei handelbar: 97.07%
Rückkaufquote: -17.94%
Mitarbeiter: 23
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 598.17%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 7.93
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -138.26%
Eigenkaprendite: -190.18%
>CARDIOL Peer Group
Gesundheit, Herz-Kreislauf- Behandlung/ Kardiologie
 
03.11.26 - 23:24
Cardiol Therapeutics drops after launching a $75M ATM offering (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.11.26 - 23:06
Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC (PR Newswire)
 
TORONTO, Nov. 3, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it has entered into a sales......
23.09.26 - 12:03
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™′s Efficacy (PR Newswire)
 
Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk.......
16.09.26 - 14:03
Cardiol Therapeutics raises over US$7M through warrant exercises (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.09.26 - 13:30
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds (PR Newswire)
 
Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in recurrent pericarditis and extends cash runway into H1 2028. TORONTO, Sept. 16, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage......
14.09.26 - 17:24
Cardiol Therapeutics auf H.C. Wainwright Konferenz: Zulassungsstudie vor Abschluss, Daten im ersten Quartal erwartet (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.09.26 - 23:06
Cardiol Therapeutics files US$150M base shelf prospectus (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.09.26 - 23:03
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission (PR Newswire)
 
TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short......
09.09.26 - 13:36
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
 
TORONTO, Sept. 9, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......
24.08.26 - 19:45
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? (Zacks)
 
Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out....
13.08.26 - 15:21
Cardiol Therapeutics GAAP EPS of -C$0.05 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.08.26 - 16:01
Cardiol Therapeutics bei Canaccord Genuity: Phase-III-Katalysator rückt näher (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.26 - 13:30
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity′s 46th Annual Growth Conference (PR Newswire)
 
TORONTO, Aug. 5, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......
14.07.26 - 13:30
Cardiol Therapeutics′ Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association (PR Newswire)
 
• Peer-reviewed JAHA publication strengthens the foundation for Cardiol's pivotal Phase III MAVERIC trial as enrollment nears completion. TORONTO, July 14, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences......
09.07.26 - 13:31
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit (PR Newswire)
 
TORONTO, July 9, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......
25.06.26 - 13:30
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders (PR Newswire)
 
TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces the results from its Annual General Meeting of......
23.06.26 - 13:30
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT (PR Newswire)
 
TORONTO, June 23, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company's virtual Annual General......
14.05.26 - 13:30
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ (PR Newswire)
 
TORONTO, May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a......
07.05.26 - 13:31
Cardiol Therapeutics′ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association (PR Newswire)
 
Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment. TORONTO, ON, May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ:......
28.04.26 - 13:30
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program (PR Newswire)
 
Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia University–NewYork-Presbyterian, NYU Langone Health, Lenox Hill Hospital/Northwell Health, and Houston Methodist Hospital. Growing......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Schriftsteller kann die Welt im besten Fall beunruhigen, im seltensten Fall beeinflussen - verändern nie. - Friedrich Dürrenmatt
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!